(Total Views: 348)
Posted On: 01/07/2018 9:23:43 PM
Post# of 72440
Indeed it was a doozy. That was during the white hot immunotherapy craze - a perfect storm if you will.
Not sure why he thinks our pipeline trumps theirs. They only had one drug but it was worth over $40B (the $21B mentioned was for half the sales).
I suppose it's possible a fully developed Brilacidin platform could be worth that. Kevetrin also has the potential to be larger. We're a long way from both though.
Let's focus on 1% of that success and get our market cap back to $400M in 2018. From there we can dream of $4B and beyond.
Go IPIX!
Not sure why he thinks our pipeline trumps theirs. They only had one drug but it was worth over $40B (the $21B mentioned was for half the sales).
I suppose it's possible a fully developed Brilacidin platform could be worth that. Kevetrin also has the potential to be larger. We're a long way from both though.
Let's focus on 1% of that success and get our market cap back to $400M in 2018. From there we can dream of $4B and beyond.
Go IPIX!
(1)
(2)
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
Scroll down for more posts ▼
